1. Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group
- Author
-
Steven E. Lipshultz, Allen M. Goorin, Judith K. Sato, Laurel J. Steinherz, Cindy L. Schwartz, Mark L. Bernstein, Holcombe E. Grier, Lisa A. Teot, Paul A. Meyers, Mark Krailo, Mark C. Gebhardt, Leonard H. Wexler, Meenakshi Devidas, and John H. Healey
- Subjects
Oncology ,medicine.medical_specialty ,Chemotherapy ,Cardiotoxicity ,Ifosfamide ,business.industry ,medicine.medical_treatment ,Hematology ,030204 cardiovascular system & hematology ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,Pediatrics, Perinatology and Child Health ,medicine ,Osteosarcoma ,Methotrexate ,Doxorubicin ,Dexrazoxane ,business ,Etoposide ,medicine.drug - Abstract
Background Although chemotherapy has improved outcome of osteosarcoma, 30–40% of patients succumb to this disease. Survivors experience substantial morbidity and mortality from anthracycline-induced cardiotoxicity. We hypothesized that the cardioprotectant dexrazoxane would 1) support escalation of the cumulative doxorubicin dose (600 mg/m2) and 2) not interfere with the cytotoxicity of chemotherapy measured by necrosis grading in comparison to historical control data.9
- Published
- 2015
- Full Text
- View/download PDF